Login  

 

The article you requested is

Lurasidone: A Clinical Overview

J Clin Psychiatry 2011;72(suppl 1):24-28
10.4088/JCP.10075su1.05

Lurasidone is a newsecond-generation (atypical) antipsychotic approved for the treatment of schizophrenia in adults. The recommended dose is 40–80 mg given oncedaily, with no titration needed. Lurasidone should be taken with food.The tolerability profile of lurasidone is noteworthy in terms of a goodweight and metabolic profile and no cardiovascular adverse effects suchas orthostatic hypotension or prolongation of the QTc interval.Lurasidone is associated with some somnolence, akathisia, nausea, andparkinsonism, especially early in treatment. Its preclinical profilesuggested it might be helpful for cognitive or depressive symptoms;early findings have shown some benefit in these areas, but additionalstudies are needed. Lurasidone may be particularly helpful for patientswith schizophrenia who are overweight or have endocrine problems(diabetes, dyslipidemia) or comorbid cardiovascularconditions.

(JClin Psychiatry 2011;72[suppl 1]:24–28)

Corresponding author: John M. Kane, MD, The Zucker Hillside Hospital, 75-59263rd St, Glen Oaks, NY (psychiatry@nshs.edu).